Noopur Raje: Welcome to the Myeloma Session from VJHemOnc. It is my great pleasure to welcome a fantastic panel for a discussion on the recently concluded ASCO and EHA meetings. We’re going to be talking all myeloma, from new diagnosis to some of the new and exciting things we have in the myeloma space. And to discuss all of this, I have the pleasure of inviting Dr Katja Weisel, she is the Deputy…
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a study exploring cytogenetic and molecular associations with outcomes…
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context…
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his excitement for the upcoming 10th World Congress on Controversies in Multiple Myeloma (COMy), which is…
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, introduces the PHOEBUS study (NCT05762211), a Phase IIb trial investigating the use of MaaT003,…
Thomas Fox, MbChB, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses an individualized approach to assessing potential risks of bone marrow…
Alex Rampotas, MD, University College London, London, UK, summarizes a talk on the role of donor lymphocyte infusion (DLI) in the post-allogenic stem cell transplant…
Rémy Duléry, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the main side effects associated with post-transplant cyclophosphamide (PTCy) as prophylaxis for graft-versus-host disease (GvHD) following…
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…
